Inhibrx Biosciences, Inc. INBX Business Segments — Other research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — other research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — other research and development?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — other research and development of $2.91M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s business segments — other research and development changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — other research and development decreased by 7.8% year-over-year, from $3.15M to $2.91M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — other research and development?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — other research and development has grown at a -12.2% compound annual growth rate (CAGR), from $16.21M to $12.5M.
- What does business segments — other research and development mean?
- Encompasses miscellaneous research and development expenditures not categorized under clinical trials or personnel costs. This provides visibility into the broader operational support and auxiliary activities required to maintain the segment's innovation pipeline.